The GeneCellNano Flagship develops new biological drugs, so-called ATMP products, biomarkers and diagnostics for common chronic diseases. The objective of the Flagship is to significantly increase domestic and foreign funding for gene, cell and nanotechnology and to introduce new effective treatments for severe chronic diseases. The aim is also to create new jobs and businesses in the biotechnology and pharmaceutical sectors. This will contribute to the development and economic welfare of Finnish society.
The Flagship brings together all of Finland’s leading gene, cell and nanotherapy researchers, clinical operators, companies and third-sector actors. The cooperation will create a new kind of ecosystem that combines public and private actors and has excellent opportunities to become an international leader in a rapidly developing sector. The Flagship combines innovative basic research, excellent production techniques, long clinical experience and a strong and diverse network of international connections.
- Director: Academy Professor Seppo Ylä-Herttuala, University of Eastern Finland
- Number of researchers: around 170
- Host organisations: University of Eastern Finland, University of Oulu, University of Helsinki, Aalto University and Finnish Red Cross Blood Service